Home  |  Contact

UniProtKB/Swiss-Prot O60313: Variant p.Leu939Pro

Dynamin-like 120 kDa protein, mitochondrial
Gene: OPA1
Variant information

Variant position:  939
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Leucine (L) to Proline (P) at position 939 (L939P, p.Leu939Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In OPA1; impairs protein folding; loss of function in promoting mitochondrial fusion.
Any additional useful information about the variant.



Sequence information

Variant position:  939
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  960
The length of the canonical sequence.

Location on the sequence:   EDGEKKIKLLTGKRVQLAED  L KKVREIQEKLDAFIEALHQE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EDGEKKIKLLTGKRVQLAEDLKKVREIQEKLDAFIEALHQE

Mouse                         EDGEKKVKLLTGKRVQLAEDLKKVREIQEKLDAFIEALHQE

Rat                           EDGEKKVKLLTGKRVQLAEDLKKVREIQEKLDAFIEALHQE

Chicken                       EDNEKKVKLLTGKRVQLAEDLKKVREIQEKLEAFIEALHQE

Zebrafish                     EDNEKKVQLITGRRVQLAEDLKKVREIQEKLEAFIEALHKE

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 88 – 960 Dynamin-like 120 kDa protein, mitochondrial
Chain 195 – 960 Dynamin-like 120 kDa protein, form S1
Topological domain 114 – 960 Mitochondrial intermembrane
Coiled coil 895 – 960


Literature citations

Mutation spectrum and splicing variants in the OPA1 gene.
Delettre C.; Griffoin J.-M.; Kaplan J.; Dollfus H.; Lorenz B.; Faivre L.; Lenaers G.; Belenguer P.; Hamel C.P.;
Hum. Genet. 109:584-591(2001)
Cited for: PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2); ALTERNATIVE SPLICING; TISSUE SPECIFICITY; VARIANTS OPA1 GLN-290; ARG-785 AND PRO-939;

OPA1 disease alleles causing dominant optic atrophy have defects in cardiolipin-stimulated GTP hydrolysis and membrane tubulation.
Ban T.; Heymann J.A.; Song Z.; Hinshaw J.E.; Chan D.C.;
Hum. Mol. Genet. 19:2113-2122(2010)
Cited for: FUNCTION; CATALYTIC ACTIVITY; SUBUNIT; CHARACTERIZATION OF VARIANTS OPA1 GLU-300; VAL-439; HIS-445; ARG-545; LYS-728; ARG-785 AND PRO-939; CHARACTERIZATION OF VARIANTS VARIANT DOA+ THR-357; VAL-439; HIS-445; ARG-545 AND ASP-910;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.